| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 14 Nov 2025 | 4 Nov 2025 |
| Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half year ended September 30 2025 We would like to inform you that the Board of Directors has at its meeting held today, i.e. November 14, 2025, inter-alia, considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025. The same were also reviewed by the Audit Committee in its meeting held on November 14, 2025. A copy of the said results along with the Limited Review Report is enclosed herewith. Please find enclosed herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025. The same were also reviewed by the Audit Committee in its meeting held on November 14, 2025. (As Per BSE Announcement Dated on:14.11.2025) Please find enclosed herewith newspaper copies of the Extract of Statement of Unaudited Financial Results for quarter and half year ended September 30,2025. (As Per BSE Announcement Dated on 15.11.2025) | ||
| Board Meeting | 14 Aug 2025 | 4 Aug 2025 |
| Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30 2025 The Board has considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2025. The same was also reviewed by the Audit Committee in its meeting held on August 13, 2025. A copy of the said results along with the Limited Review Report is enclosed herewith (As Per BSE Announcement Dated on: 14.08.2025) | ||
| Board Meeting | 30 May 2025 | 24 May 2025 |
| Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve the Audited Financial Results for the Quarter and Financial Year ended March 31 2025 and passing over of dividend on equity as well as preference shares for the said Financial Year Outcome of Board Meeting held on May 30, 2025. Passing over of dividend on the equity as well as preference shares of the Company for the financial year 2024-25, on account of losses during the year. (As Per BSE Announcement Dated on 30.05.2025) | ||
| Board Meeting | 14 Feb 2025 | 31 Jan 2025 |
| PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31 2024. The trading window of the Company shall remain closed for all Designated Persons till February 16 2025. Please find attached outcome of the Board Meeting of Panacea Biotec Limited held on February 14, 2025 (As Per Bse Announcement Dated on 14.02.2025) | ||
Such a contract symbolizes Panacea Biotec's continued commitment toward global health by contributing its share of the fight against polio, a deadly disease prevalent in many pockets of the world.
Panacea Biotec's stock has seen a 37% gain over the past six months. Panacea Biotec's stock has gained a total of 76% in the last one year.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
